WO2008056375A3 - Formulations pharmaceutiques comprenant du valsartan - Google Patents

Formulations pharmaceutiques comprenant du valsartan Download PDF

Info

Publication number
WO2008056375A3
WO2008056375A3 PCT/IN2007/000516 IN2007000516W WO2008056375A3 WO 2008056375 A3 WO2008056375 A3 WO 2008056375A3 IN 2007000516 W IN2007000516 W IN 2007000516W WO 2008056375 A3 WO2008056375 A3 WO 2008056375A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
angiotensin
antagonist
prepared
valsartan
Prior art date
Application number
PCT/IN2007/000516
Other languages
English (en)
Other versions
WO2008056375A2 (fr
Inventor
Anirudha Kute
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Original Assignee
Lupin Ltd
Anirudha Kute
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd, Anirudha Kute, Nikhil Prabhakar Malewar, Makarand Krishnakumar Avachat filed Critical Lupin Ltd
Publication of WO2008056375A2 publication Critical patent/WO2008056375A2/fr
Publication of WO2008056375A3 publication Critical patent/WO2008056375A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant un antagoniste de l'angiotensine II, ladite composition pharmaceutique étant préparée par granulation en voie humide ; une composition pharmaceutique comprenant un antagoniste de l'angiotensine II et un ou plusieurs diurétiques, ladite composition pharmaceutique étant préparée par granulation en voie humide ; une composition pharmaceutique préparée par granulation en voie humide comprenant un agent actif comprenant une quantité efficace d'un antagoniste de l'angiotensine II et des additifs acceptables du point de vue pharmaceutique, l'agent actif étant présent en quantité inférieure à 35 % en poids sur la base du poids total de la composition pharmaceutique.
PCT/IN2007/000516 2006-11-09 2007-11-02 Formulations pharmaceutiques comprenant du valsartan WO2008056375A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1200/KOL/2006 2006-11-09
IN1200KO2006 2006-11-09

Publications (2)

Publication Number Publication Date
WO2008056375A2 WO2008056375A2 (fr) 2008-05-15
WO2008056375A3 true WO2008056375A3 (fr) 2008-07-10

Family

ID=39322620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000516 WO2008056375A2 (fr) 2006-11-09 2007-11-02 Formulations pharmaceutiques comprenant du valsartan

Country Status (1)

Country Link
WO (1) WO2008056375A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139473A1 (fr) * 2007-03-29 2010-01-06 Alembic Limited Formulations de comprimés de valsartan
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
KR101509489B1 (ko) * 2008-11-10 2015-04-08 (주)아모레퍼시픽 발사르탄을 함유하는 고형 경구제형의 제조 방법
WO2011102702A2 (fr) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
CN102247376B (zh) * 2011-08-15 2012-11-28 华润赛科药业有限责任公司 复方缬沙坦氢氯噻嗪固体制剂及其制备方法
KR101446603B1 (ko) * 2011-11-22 2014-10-07 주식회사 인트로팜텍 텔미사르탄을 포함하는 단층정 복합 제제
WO2013098578A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
WO2013098576A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique de valsartan à libération immédiate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2005082329A2 (fr) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Procede de preparation de formes posologiques solides de valsartan et d'hydrochlorthiazide
WO2005089720A1 (fr) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Comprimes a base de valsartan et procede de preparation associe
EP1674080A1 (fr) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2005082329A2 (fr) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Procede de preparation de formes posologiques solides de valsartan et d'hydrochlorthiazide
WO2005089720A1 (fr) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Comprimes a base de valsartan et procede de preparation associe
EP1674080A1 (fr) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan

Also Published As

Publication number Publication date
WO2008056375A2 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008056375A3 (fr) Formulations pharmaceutiques comprenant du valsartan
WO2005089729A3 (fr) Formulations galeniques de composes organiques
WO2008140507A8 (fr) Formulations de nanoparticules et de polymères pour les analogues, les antagonistes et les formulations de l'hormone thyroïde et leurs utilisations
WO2008051291A3 (fr) Nanoparticule et formes polymères d'analogues et d'antagonistes de l'hormone thyroïdienne et leurs formulations
WO2006084164A3 (fr) Systeme d'administration a retention gastrique et a liberation lente
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2009063222A3 (fr) Compositions solides
WO2008023016A3 (fr) Formulations galéniques de composés organiques
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007098128A3 (fr) Formules liquides de phényléphrine
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2007002823A3 (fr) Formulations d'oestrogenes conjugues et de bazedoxifene
WO2005084648A8 (fr) Compositions pharmaceutiques comprenant du candesartan cilexetil
WO2007048027A3 (fr) Combinaison de composes organiques
WO2006008173A3 (fr) Formulations pharmaceutiques
WO2008123582A1 (fr) Composé de tétrahydroisoquinoline
WO2009045795A3 (fr) Formulations galéniques de composés organiques
WO2007084212A3 (fr) Composition biologiquement active contenant de l'éthylcellulose
WO2010038091A9 (fr) Composition pharmaceutique a combinaison stable
WO2008003050A3 (fr) Formulations de nitrate de gallium
EP1935417A4 (fr) Composition à utiliser pour la prévention d'un état hypoglycémique
WO2007009691A3 (fr) Combinaison de substances active s
WO2008075984A3 (fr) Préparation de comprimé
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
WO2004071385A3 (fr) Utilisation de dipyridamole en association avec de l'acide acetylsalicylique et un antagoniste de l'angiotensine ii aux fins de la prevention des accidents cerebro-vasculaires

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07849683

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07849683

Country of ref document: EP

Kind code of ref document: A2